Literature DB >> 185951

Effect of treatment with exogenous interferon, polyinosinic acid-polyctyidylic acid or polyinosinic acid-polycytidylic acid-poly-L-lysine complex on encephalomyocarditis virus infections in mice.

G A Olsen, E R Kern, L A Glasgow, J C Overall.   

Abstract

The effect of treatment with exogenous interferon was compared with two interferon inducers, polyinosinic acid-polycytidylic acid [poly(I:C)] and [poly(I:C)]-poly-l-lysine complex (P-L-L complex), in two model encephalomyocarditis virus infections of mice. Although both inducers stimulated the production of interferon, the peak serum levels induced by P-L-L complex were five- to eightfold greater than those induced with poly(I:C). When encephalomyocarditis virus was inoculated by either the intraperitoneal or the intranasal route, interferon and both of the inducers protected mice against mortality and prolonged the mean day of death when the compounds were given prior to or immediately after viral challenge. In general, treatment with interferon was not as successful as treatment with poly(I:C) or P-L-L complex. In these infections, P-L-L complex appeared to be the most effective agent in that successful treatment resulted when drug therapy was initiated as late as 48 h after virus inoculation. An examination of the effect of treatment on the pathogenesis of the infection indicated that protection was associated with the prevention of viremia and subsequent seeding of target organs, particularly the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 185951      PMCID: PMC429812          DOI: 10.1128/AAC.10.4.668

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. II. Effect of multiple doses of polyriboinosinic-polyribocytidylic acid on viral pathogenesis.

Authors:  D A Stringfellow; J C Overall; L A Glasgow
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

2.  Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis.

Authors:  D A Stringfellow; J C Overall; L A Glasgow
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Double-stranded RNAs (poly I:C) in the prevention of viral infections.

Authors:  M R Hilleman
Journal:  Arch Intern Med       Date:  1970-07

4.  Protection against herpes virus and encephalomyocarditis virus encephalitis with a double-stranded RNA inducer of interferon.

Authors:  L W Catalano; S Baron
Journal:  Proc Soc Exp Biol Med       Date:  1970-02

5.  Inhibition of biologic activity of poly I: poly C by human plasma.

Authors:  J J Nordlund; S M Wolff; H B Levy
Journal:  Proc Soc Exp Biol Med       Date:  1970-02

Review 6.  Coxsackieviruses and echoviruses.

Authors:  D M McLean
Journal:  Am J Med Sci       Date:  1966-03       Impact factor: 2.378

7.  Late therapy with an interferon stimulator in an arbovirus encephalitis in mice.

Authors:  M Worthington; S Baron
Journal:  Proc Soc Exp Biol Med       Date:  1971-01

8.  Exogenous interferon in animals and its clinical implications.

Authors:  N B Finter
Journal:  Arch Intern Med       Date:  1970-07

9.  Interferon as an antiviral agent in vivo: quantitative and temporal aspects of the protection of mice against Semliki Forest virus.

Authors:  N B Finter
Journal:  Br J Exp Pathol       Date:  1966-08

10.  Comparative study of the efficacy of different forms of interferon therapy in the treatment of mice challenged intranassaly with vesicular stomatitis virus (VSV).

Authors:  E De Clercq; P De Somer
Journal:  Proc Soc Exp Biol Med       Date:  1971-10
View more
  7 in total

1.  Treatment of a murine cytomegalovirus infection with exogenous interferon, polyinosinic-polycytidylic acid, and polyinosinic-polycytidylic acid-poly-L-lysine complex.

Authors:  E R Kern; G A Olsen; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

2.  Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy.

Authors:  H Heremans; A Billiau; P De Somer
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

3.  Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice.

Authors:  L R Crane; D A Milne; J C Sunstrum; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

4.  Antiviral activity of bacteria-derived human alpha interferons against encephalomyocarditis virus infection of mice.

Authors:  P K Weck; E Rinderknecht; D A Estell; N Stebbing
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

5.  Antiviral activity of BL-3849A, a low-molecular-weight oral interferon inducer.

Authors:  E R Kern; J R Hamilton; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

6.  Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.

Authors:  J Hilfenhaus; H Christ; R Köhler; H Moser; H Kirchner; H B Levy
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

7.  Use of viral infections in animal models to assess changes in the immune system.

Authors:  E R Kern
Journal:  Environ Health Perspect       Date:  1982-02       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.